What Ocular Science does

Ocular Science is a private biotech company founded in 2015 and headquartered in El Segundo, California. The company develops and markets compounded ophthalmic pharmaceutical products for the corrective eye care industry, with applications spanning post-operative care following eye surgery, combination therapy regimens, and low-dose atropine treatments for myopia management. Its core technical capability is multi-medication compounding — the ability to combine multiple drugs into a single ophthalmic drop — delivered through its wholly-owned affiliate OSRX Pharmaceuticals, a 503B-registered outsourcing pharmacy that produces, distributes, and dispenses these formulations under the regulatory framework established by the Drug Quality and Security Act.

The company sells its products on a physician-directed, prescription-based model: ophthalmologists and optometrists prescribe OSRX-compounded formulations to their patients, with distribution handled directly through the 503B pharmacy channel. Ocular Science's go-to-market is anchored by a Medical Advisory Board of 30-32 leading ophthalmologists and optometrists who serve as both clinical advisors and key opinion leader prescribers, supplemented by a national sales team led by a Chief Commercial Officer and VP of Sales. The board's two co-founders — Dr. Damien Goldberg (CMO, also managing partner at Wolstan & Goldberg Eye Associates) and Dr. Francis Mah (Chief MAB Member, Director at Scripps Clinic) — provide deep clinical credibility and direct prescribing relationships.

Ocular Science monetizes through per-prescription compounded product sales rather than software licensing or subscription models; pricing is not publicly disclosed. The company has raised approximately $16.7M in total disclosed funding, including a $16.5M round led by Chicago Atlantic Group in January 2026. Its customer base is horizontally distributed across U.S. ophthalmology and optometry practices with no single anchor account, and operations remain entirely domestic. The company has no disclosed AI/ML capabilities and does not operate a software platform — its competitive positioning rests on compounding expertise, regulatory authorization, prescriber relationships, and cost advantages versus multi-drop branded regimens.

Name

Ocular Science

Legal name

Ocular Science, Inc.

Website

https://ocularscience.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Ocular Science is a private biotech company that develops and markets compounded ophthalmic pharmaceuticals — including post-operative care, combination therapy, and low-dose atropine products — through its 503B pharmacy affiliate OSRX, selling to U.S. ophthalmologists and optometrists via physician-directed prescription channels.

Ownership category

akta.pro rank

Product category

Compounded Ophthalmic Pharmaceuticals

NAICS

Ophthalmic Goods Manufacturing (339115)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Ophthalmology Specialty Pharmaceuticals (HLAIACAK)

akta.pro secondary industries

Ophthalmology Pharmaceuticals (HLAIAAAL), Ocular Drug Delivery Devices (Eye Droppers/Inserts) (HLAHAIAL)

Keywords

• Compounded ophthalmic medications
• 503B pharmacy products
• Post-operative eye care
• Low-dose atropine treatment
• Combination therapy drops

Headquarters

HQ city

Manhattan Beach

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Compounded Ophthalmic Pharmaceuticals: Production, marketing, and sales of compounded ophthalmic products through OSRX 503B pharmacy affiliate. Products include medications for post-operative care, combination therapy drops, and low-dose atropine treatments for eye conditions.
2. Physician-Directed Product Sales: Sale of corrective eye care products to physicians and their patients in the ophthalmology and optometry markets, with products being prescribed and dispensed through eye care practices.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

Ocular Science develops and markets compounded ophthalmic pharmaceutical products through its 503B pharmacy affiliate OSRX Pharmaceuticals. The company specializes in creating therapeutic solutions for post-operative care, combination therapy drops, and low-dose atropine treatments for the corrective eye care industry, with the ability to compound multiple medications into a single ophthalmic drop to promote patient compliance and affordability.

Product overview

Ocular Science is a biotech company focused on developing and marketing compounded ophthalmic products through its 503B pharmacy affiliate OSRX Pharmaceuticals. The company specializes in creating therapeutic solutions that combine multiple medications into single drops, targeting the corrective eye care market. Their product portfolio centers on post-operative care medications, combination therapies, and low-dose atropine treatments, all designed to improve patient compliance and affordability.

Differentiator

Problem solved

Functional benefit

Products and services

• Compounded Ophthalmic Products Therapeutic compounded ophthalmic products including post-operative care medications, combination therapy drops that combine multiple medications into a single drop, and low-dose atropine treatments for myopia management. Sold to ophthalmologists, optometrists, and eye care practices for prescribing to their patients.

Named customers4 records

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• OSRX Pharmaceuticals (OSRX)coreStrategic or Co-development PartnerOSRX is Ocular Science's 503B pharmacy affiliate that specializes in compounding ophthalmic medications. Through this partnership, Ocular Science blends practical solutions with paradigm-shifting innovations to compound multiple medications into a single drop that promotes compliance and affordability. OSRX handles the production and pharmacy operations while Ocular Science focuses on product development, marketing, and sales.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• ImprimisRx (Harrow Health): Operates a 503B compounding pharmacy focused on ophthalmic formulations, including combination and preservative-free drops for post-surgical care. It is the closest direct analog to OSRX in business model, regulatory pathway, and target prescriber base (ophthalmologists and optometrists).

Broad incumbents

• Bausch + Lomb (Bausch Health): Major incumbent in ophthalmic pharmaceuticals and surgical products, including post-cataract and dry eye therapeutics. Competes with OSRX's compounded post-op drops through branded, FDA-approved alternatives and has far larger sales coverage and R&D resources.
• Alcon: Global leader in surgical ophthalmology and ophthalmic pharmaceuticals. Its post-cataract drop portfolio and surgical IOL franchise directly intersect with the prescriber base Ocular Science targets through its MAB, and its CEO's previous employer (Alcon) gives Ocular Science's leadership deep familiarity with this competitor's playbook.
• Allergan / AbbVie: Broad incumbent in ophthalmic pharmaceuticals, especially dry eye (Restasis), post-surgical inflammation, and ocular surface disease. Represents the kind of FDA-approved branded competitor that could disrupt compounded alternatives if it launches a superior fixed-dose combination drop.
• Sun Pharmaceutical Industries: Large generic and specialty pharmaceutical manufacturer with a significant ophthalmic portfolio (including post-cataract steroid/NSAID drops). Competes with OSRX on price-sensitive generic equivalents of single-agent post-op medications that OSRX combines into multi-drug drops.

Emerging players

• Nicox: Clinical-stage ophthalmic company developing novel therapeutics for glaucoma and ocular surface disease. Comparable as a smaller, focused ophthalmic pharma targeting prescribers overlapping with OSRX's MAB, though concentrated in prescription drugs rather than compounding.
• Eyenovia: Emerging ophthalmic company with a novel micro-dose delivery platform for myopia management and other indications. Directly relevant as a competitor in low-dose atropine for pediatric myopia, a category Ocular Science is expanding into.
• Kala Pharmaceuticals: Emerging ophthalmic specialty pharma focused on ocular surface disease and inflammation. Comparable as a smaller, focused ophthalmic pharma developing branded alternatives in the same post-surgical inflammation and dry eye prescribing universe as OSRX.
• Oyster Point Pharma (Viatris): Specialty ophthalmic company (now part of Viatris) developing therapies for dry eye disease, including nasal spray delivery—an adjacent ocular surface competitor targeting the same ophthalmology/optometry prescribers as OSRX products.

Regional players

• Apotex: Generic pharmaceutical manufacturer with a significant ophthalmic portfolio including post-cataract drops. Comparable as a price-disciplined competitor on the individual generic agents that OSRX combines into multi-medication formulations.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/ocularscience

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries1 record

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ocular Science